---
title: "Shandong Boan Biotechnology Transfers 11.99 Million H Shares to Complete Minority Stake Deal"
description: "Shandong Boan Biotechnology Co. Ltd. will transfer 11,986,600 H shares to the Issuer on January 27, 2026, as part of a minority stake deal initiated by its controlling shareholder, Luye Pharma Group L"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273712418.md"
published_at: "2026-01-26T14:01:13.000Z"
---

# Shandong Boan Biotechnology Transfers 11.99 Million H Shares to Complete Minority Stake Deal

> Shandong Boan Biotechnology Co. Ltd. will transfer 11,986,600 H shares to the Issuer on January 27, 2026, as part of a minority stake deal initiated by its controlling shareholder, Luye Pharma Group Ltd. The board expects no material adverse effects on the company's operations from this transaction. This announcement follows a subscription agreement related to Exchangeable Preference Shares.

Shandong Boan Biotechnology Co. Ltd. has announced that its controlling shareholder, Luye Pharma Group Ltd., through its wholly-owned subsidiary Shandong Luye Pharmaceutical Co., Ltd., will transfer 11,986,600 H shares of Boan Biotechnology to the Issuer on 27 January 2026. This transfer is part of the completion of a previously announced proposed transfer, in accordance with the terms of a subscription agreement related to Exchangeable Preference Shares. The board of Boan Biotechnology does not expect the transaction to have any material adverse effect on the group’s business operations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260126-12001549), on January 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [560600.CN - Founder Fubon CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/560600.CN.md)
- [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [159859.CN - Tianhong CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159859.CN.md)
- [06955.HK - BOAN BIOTECH](https://longbridge.com/en/quote/06955.HK.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [159615.CN - China Southern Hang Seng Biotech ETF(QDII)](https://longbridge.com/en/quote/159615.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hangzhou Jiuyuan’s Semaglutide Biosimilar Jikeqin Advances Toward China Market Approval | Hangzhou Jiuyuan Gene Engineering Co Ltd has developed Jikeqin, a biosimilar of semaglutide for weight management. The d | [Link](https://longbridge.com/en/news/276936312.md) |
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/en/news/276822785.md) |
| HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China | HBM Holdings (SEHK:2142) has entered an exclusive partnership with Solstice Oncology for its clinical asset HBM4003 outs | [Link](https://longbridge.com/en/news/276700073.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |
| China's Jiuyuan Genetic seeks approval for Wegovy biosimilar | Jiuyuan Genetic Biopharmaceutical has applied for approval to sell its biosimilar version of Wegovy in China, ahead of a | [Link](https://longbridge.com/en/news/276994337.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.